News
FDA Brings ‘Lasting’ Relief for Painful Crohn’s Disease Symptoms!
The FDA has approved Omvoh by Eli Lilly as the first biological treatment for moderately to severely active Crohn’s disease in over 15 years. Clinical trials showed significant remission and intestinal healing, offering new hope for long-term disease control.
United States: The US Food and Drug Administration has granted approval for mirikizumab-mrkz, sold as Omvoh by Eli Lilly and Company, as a treatment for moderately to severely active Crohn disease in adults.
More about the news
Omvoh binds to interleukin-23p19, which is involved in the regulation of inflammation in the intestines.
Omvoh is the first biological treatment for Crohn’s disease and a company that has submitted phase 3 efficacy data for the two-year treatment in more than 15 years, US News reported.
$LLY Omvoh is now FDA-approved for treating moderately to severely active Crohn’s disease in adults, providing a new treatment option for patients: https://t.co/n2UHa0Y3UH#Omvoh #CrohnsDisease #IBD #FDAApproval #EliLilly #HealthcareInnovation
— BioMedWire (@BioMedWire) January 17, 2025
The approval has been achieved thanks to the results of the multicenter, double-blind, placebo-controlled, phase 3 VIVID-1 trial involving adult patients with moderately to severely active Crohn’s disease, intolerant or having failed corticosteroids, immunomodulators, and/or biologic agents.
For this investigation, patients were randomly allocated to a placebo or Omvoh.
Details of the study
The patients in the placebo arm who did not respond clinically at 12 weeks were then crossed over to active drug treatment Omvoh.
Both primary endpoints were attained; 53 and 36 percent of patients treated with Omvoh were in clinical remission at one year, and 46 and 23 percent of patients treated with Omvoh and placebo, respectively, presented discernible healing of the intestinal lining at one year.
FDA Approves Omvoh for Moderately to Severely Active Crohn Disease https://t.co/U0Q9U9j8NQ
— Drugs.com (@Drugscom) January 17, 2025
According to Daniel M. Skovronsky, M.D., Ph.D., chief scientific officer and president of Lilly Research Laboratories and Lilly Immunology, “With Omvoh approved in both Crohn’s disease and ulcerative colitis, more patients now have a treatment option that may provide long-term disease control and address key symptoms that matter most to them, reflecting Lilly’s ongoing commitment to elevate care and improve outcomes for patients,” US News reported.
Did the Romans Really Brush with Pee?
The Blood Vessels in Your Body Could Wrap Around the Earth 2.5 Times
Your Small Intestine Is Longer Than a Giraffe’s Neck!
Why We Don’t Act Out Our Dreams—And What Happens When We Do
A Sneeze: Nature’s High-Powered Air Cannon
The Hidden Dangers of Prolonged Sitting: Why Movement Is Non-Negotiable
Fun Fact: Laughing 100 times burns as many calories as 10 minutes on a stationary bike
-
News4 weeks agoManaging Anemia: Foods Rich in Iron and B Vitamins
-
Health Facts1 week agoThe Hidden Dangers of Prolonged Sitting: Why Movement Is Non-Negotiable
-
News6 days agoWhy We Don’t Act Out Our Dreams—And What Happens When We Do
-
Health Facts1 week agoA Sneeze: Nature’s High-Powered Air Cannon
-
Health Facts5 days agoYour Small Intestine Is Longer Than a Giraffe’s Neck!
-
Health Facts2 weeks agoFun Fact: Laughing 100 times burns as many calories as 10 minutes on a stationary bike
-
Health Facts2 days agoThe Blood Vessels in Your Body Could Wrap Around the Earth 2.5 Times
-
Fun Facts9 hours agoDid the Romans Really Brush with Pee?